SPTBN4: A Potential Drug Target and Biomarker (G57731)

Target Name: SPTBN4

NCBI ID: G57731

SPTBN4

SPTBN4: A Potential Drug Target and Biomarker

Spermidine-containing peptides (SPTs) are a class of biomarkers that have been identified as potential drug targets in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the most promising of these biomarkers is SPTBN4, a protein that is expressed in various and tissues cells throughout the body.

SPTBN4 is a 26-kDa protein that is composed of two distinct regions: a N-terminal region that contains a spectrin-like domain, and a C-terminal region that contains a unique set of domains that are different from those found in typical spectins . The N-terminal region of SPTBN4 contains a nucleotide-binding oligomerization domain (NBO domain), which is responsible for the protein's stability and stability against various environmental conditions, such as high temperature and high pH. The C-terminal region of SPTBN4 contains a PLA domain (LD domain) and a basic domain (B domain), which are involved in the protein's stability and interactions with other cellular components.

SPTBN4 has been shown to play a role in various cellular processes, including cell signaling, DNA replication, and cell survival. For example, SPTBN4 has been shown to be involved in the regulation of cell apoptosis, which is the process by which cells die naturally in response to external stressors. In addition, SPTBN4 has been shown to be involved in the regulation of cell proliferation, and has been shown to inhibit the growth of various cancer cell lines.

SPTBN4 has also been shown to be a potential drug target in neurodegenerative diseases. For example, SPTBN4 has been shown to be involved in the regulation of neurotransmitter release from neurons, which is critical for the proper functioning of the nervous system. In addition, SPTBN4 has been shown to be involved in the regulation of glial cell function, which is important for the support of nerve cells.

SPTBN4 has also been shown to be a potential biomarker for various diseases, including cancer. For example, SPTBN4 has been shown to be overexpressed in various types of cancer, and has been shown to be involved in the regulation of cell proliferation and survival. In In addition, SPTBN4 has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels form in the body.

In conclusion, SPTBN4 is a protein that has been shown to play a role in various cellular processes and has been identified as a potential drug target and biomarker. Further research is needed to fully understand the role of SPTBN4 in various diseases and to develop effective therapies based on this protein.

Protein Name: Spectrin Beta, Non-erythrocytic 4

The "SPTBN4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPTBN4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets